- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04350970
High-flow Nasal Cannula and Exercise Tolerance in COPD
Acute Effects of High-flow Nasal Cannula and Non-invasive Ventilation on Constant-load Exercise Tolerance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The patients underwent an initial clinical examination, with anthropometric evaluation, blood gas analysis, pulmonary function tests and measurement of maximum respiratory pressures. The exercise protocol started in the sector of Ergometry and Cardiopulmonary Exercise Testing. After completing the maximum incremental cardiopulmonary exercise test, two additional visits were scheduled for the three constant load tests. All patients studied underwent an evaluation of cardiopulmonary exercise testing (CPET). During maximum-incremental CPET, breath by breath: oxygen consumption (V̇O2, mL/min), carbon dioxide production (V̇CO2, mL/min), respiratory exchange rate (RER), minute ventilation VE (L/min), respiratory rate (bpm), equivalent ventilation for O2 and CO2 (V̇E/V̇O2 and V̇E/V̇CO2). In addition, cardiac monitoring was performed by 12-lead electrocardiogram (ECG) throughout the procedure. On the day of the experiment, the patients underwent two cardiopulmonary exercises with constant-load at 90% of the previously determined peak, separated by an interval of at least 1 hour.
The NIV parameters were adjusted for each patient with Trilogy 100 (Philips™). Spontaneous ventilation mode was set before the protocol for all patients, and a previous period of NIV adaptation was performed to titrate the inspiratory and expiratory pressures. The adaptation period started with the minimum Inspiratory Positive Airway Pressure (IPAP) value of 15cmH2O, and, every 2 minutes, increasing the pressure every 2 cmH2O according to the patient's tolerance.16 The Expiratory Positive Airway Pressure (EPAP) was programmed to vary between 4 and 6 cmH2O. Before the start of the examination, an adaptation was performed with the selected mask and initial ventilator settings for 20 min. No additional oxygen was offered.
The high flow system used was Optiflow® (Fisher & Paykel Healthcare, Auckland, New Zealand). Before the test, flow titration was performed for the patient, which started with the administration of a minimum gas flow of 30L/min and, every 2 minutes, the flow was increased by 5L/min according to patient tolerance. The test only started after 20 minutes of adaptation.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
CE
-
Fortaleza, CE, Brasil, 60.430-370
- Federal University Of Ceara
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Previous COPD
- FEV1 ≤ 50%
- Optimized medication
Exclusion Criteria:
- COPD Exacerbation
- Cardiac disease
- Previous neurologic disorders
- Unable to complete all protocol
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Control
The cardiopulmonary exercise test was performed with patient breathing room air.
|
All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload.
The control test was performed with no additional therapy.
|
Comparador activo: NIV
The cardiopulmonary exercise test was performed with non-invasive ventilation during the test.
|
All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload.
The NIV was used during all exercise test.
|
Comparador activo: HFNT
The cardiopulmonary exercise test was performed with a High flow nasal therapy during the test.
|
All patients underwent two cardiopulmonary exercises with constant-load at 90% of the peak workload.
The high flow nasal therapy was used during all exercise test.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Exercise dinamic hyperinflation
Periodo de tiempo: one week after all tests
|
To determine the dinamic hyperinflation during exercise test with 3-different situations , Control, NIV and HFNT.
During all testes the dinamic hyperinflation will be measured by inspiratory capacity (at rest and at the end o exercise test) and will be demonstrated as porcentage os maximum.
|
one week after all tests
|
Exercise Tolerance
Periodo de tiempo: one week after all tests
|
To determine the exercise tolerance with 3-different situations , Control, NIV and HFNT.
Time of exercise test will be measured to determine which test could be the best for COPD patients.
In additional, the workload will (treadmill inclination and speed) be check to show which intervention has the better response.
|
one week after all tests
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Dyspnea
Periodo de tiempo: one week after all tests
|
To determine the dyspnea during exercise test with 3-different situations , Control, NIV and HFNT.
After all situations, Borg scale will be performed to check the dyspnea score at the end of exercise.
|
one week after all tests
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 3.009.159
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Control
-
University Hospital, LilleTerminado
-
Takeshi MorimotoUniversity of the RyukyusActivo, no reclutandoEnfermedad de la arteria coronaria | Hipertensión | Diabetes tipo 2 | DislipidemiaJapón
-
Yonsei UniversityAún no reclutandoHipertensión | Enfermedades Renales Crónicas | DislipidemiasCorea, república de
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainDesconocidoUn Procedimiento Breve de Regulación Emocional (PbRE) para la Fibromialgia Utilizando las TIC (PbRE)Dolor crónico | FibromialgiaEspaña
-
Federal University of Health Science of Porto AlegreTerminado
-
Xuanwu Hospital, BeijingBeijing Tiantan Hospital; Peking University Third Hospital; The 306 Hospital of...DesconocidoRevascularización Cerebral | Enfermedad cerebrovascular isquémicaPorcelana
-
National Taiwan University HospitalTerminado
-
University of California, San FranciscoRetiradoLesión pulmonar aguda
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; TinyLifeTerminadoBebé muy prematuroReino Unido
-
National Taiwan University HospitalInscripción por invitaciónFunción cognitiva | Fibrilación Auricular, PersistenteTaiwán